Appendix 7.6 Distension

Study: Buchbinder 2004 ⁴³				
Outcome: Pain (pain overall) measu	ıred using Likert 0–10	scale		
Intervention ^a	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	25	6.0	2.0
Placebo (arthrogram only)		21	5.7	2.1
Intervention	Time point	No. analysed	Mean change from baseline ^b	SD
Arthrographic distension + steroid	3 weeks	25	2.5	2.5
Placebo (arthrogram only)		21	0.2	1.7
Arthrographic distension + steroid	6 weeks	25	2.4	2.7
Placebo (arthrogram only)		21	1.0	2.4
Arthrographic distension + steroid	12 weeks	25	3.1	2.4
Placebo (arthrogram only)		21	2.4	2.8
Outcome: Pain (pain overall) measu	ıred using Likert 0–10	scale – calculated values		
Intervention ^a	Time point	No. analysed	Mean	SD^d
Arthrographic distension + steroid	6 weeks	25	3.6	2.69
Placebo (arthrogram only)	6 weeks	21	4.7	2.73
Arthrographic distension + steroid	12 weeks	25	2.9	2.69
Placebo (arthrogram only)	12 weeks	21	3.3	2.73

a All interventions received concomitant home exercise.

b Baseline – follow-up value.

c Calculated for 6-week and 12-week data only.

d Imputed using R model.

Study: Buchbinder 2004 ⁴³				
Outcome: Function and disability r	neasured using SPA	ADI total score		
Intervention ^a	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	25	53.8	18.5
Placebo (arthrogram only)		21	55.7	22.6
Intervention ^a	Time point	No. analysed	Mean change from baseline	SD
Arthrographic distension + steroid	3 weeks	25	21.8	19.3
Placebo (arthrogram only)		21	4.7	19.8
Arthrographic distension + steroid	6 weeks	25	21.6	23.0
Placebo (arthrogram only)		21	16.6	21.4
Arthrographic distension + steroid	12 weeks	25	28.7	23.9
Placebo (arthrogram only)		21	24.3	25.8
Outcome: Function and disability i	neasured using the	problem elicitation tech	nique score	
Intervention ^a	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	25	172.6	48.2
Placebo (arthrogram only)		21	169.9	76.7
Intervention	Time point	No. analysed	Mean change from baseline	SD
Arthrographic distension + steroid	3 weeks	25	62.5	75.5
Placebo (arthrogram only)		21	8.7	29.0
Arthrographic distension + steroid	6 weeks	25	71.3	81
Placebo (arthrogram only)		21	25.3	34.4
Arthrographic distension + steroid	12 weeks	25	107.7	74.2
Placebo (arthrogram only)		21	53.3	70.3

a All interventions received concomitant home exercise.

Study: Buchbinder 2004 ⁴³				
Outcome: Range of movement – a	ctive abduction (°)			
Intervention ^a	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	25	79.8	27.5
Placebo (arthrogram only)		21	72.9	21.2
Intervention ^a	Time point	No. analysed	Mean change from baseline	SD
Arthrographic distension + steroid	3 weeks	25	20.2	30.2
Placebo (arthrogram only)		21	-0.2	22.5
Arthrographic distension + steroid	6 weeks	25	24.4	34.2
Placebo (arthrogram only)		21	15.5	26.1
Arthrographic distension + steroid	12 weeks	25	32.8	38.1
Placebo (arthrogram only)		21	28.3	29.9
Outcome: Range of movement – e.	xternal rotation (°)			
Intervention ^a	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	25	41.7	20.2
Placebo (arthrogram only)		21	35.8	27.0
Intervention ^a	Time point	No. analysed	Mean change from baseline	SD
Arthrographic distension + steroid	3 weeks	25	9.0	18.5
Placebo (arthrogram only)		21	3.2	19.9
Arthrographic distension + steroid	6 weeks	25	8.8	28.0
Placebo (arthrogram only)		21	15.3	33.7
Arthrographic distension + steroid	12 weeks	25	19.9	27.9
Placebo (arthrogram only)		21	17.8	29.2
Outcome: Range of movement – h	and behind back (°)			
Intervention ^a	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	25	16.0	3.9
Placebo (arthrogram only)		21	16.7	4.2
Intervention ^a	Time point	No. analysed	Mean change from baseline	SD
Arthrographic distension + steroid	3 weeks	25	3.2	3.7
Placebo (arthrogram only)		21	-0.2	3.8
Arthrographic distension + steroid	6 weeks	25	3.4	4.3
Placebo (arthrogram only)		21	1.5	4.8
Arthrographic distension + steroid	12 weeks	25	4.2	4.4
Placebo (arthrogram only)		21	3.4	5.0

a All interventions received concomitant home exercise.

Note: Other range of movement reported, which was not of relevance to this review and is therefore not presented in the data extraction table, was shoulder flexion.

Study: Buchbinder 200443

Outcome: Quality of life

Not reported

Study: Buchbinder 200443

Outcome: Other

Not reported

Study: Buchbinder 200443

Outcome: Adverse events

Total reported adverse events: arthrographic distension (n=25): 9 (36%), placebo (n=21): 1 (4%)

Pain associated with procedure: arthrographic distension (n=25): 4 (16%), placebo (n=21): 1 (4%)

Increased pain for up to 48 hours after procedure: arthrographic distension (n=25): 3 (12%), placebo (n=21): 1 (4%)

Claustrophobia at time of procedure: arthrographic distension (n=25): 1 (4%), placebo (n=21): 1 (4%)

Unsettled, anxious and hot: arthrographic distension (n=25): 0 (0%), placebo (n=21): 1 (4%)

Shoulder noisy (i.e. fluid noises): arthrographic distension (n=25): 1 (4%), placebo (n=21): 0 (0%)

Study: Gam 199886					
Outcome: Pain (pain at	rest, pain on activity)	measured using VAS 0-1	0 cm		
Intervention	Time point	No. randomised	Mean	SD	
Distension + steroid	Baseline	12	NR	NR	
Steroid injection		8	NR	NR	
Intervention	Time point	No. analysed	Mean	SD	p-value
Distension + steroid	Unclear	11	NR	NR	No difference between groups
Steroid injection		7			(p=0.1)
Outcome: Pain (analges	ic consumption)				
Intervention	Time point	No. randomised	Mean	SD	
Distension + steroid	Baseline	12	NR	NR	
Steroid injection		8	NR	NR	
Intervention	Time point	No. analysed	Mean	SD	p-value
Distension + steroid	Week 11	11	NR	NR	Analgesic consumption
Steroid injection		7			significantly lower in the distension group than in the steroid group $(p=0.008)$

NR, not reported.

Study: Gam 199886

Outcome: Function and disability

Not reported

Study: Gam 199886					
Outcome: Range of mo	ovement – passive ab	duction			
Intervention	Time point	No. randomised	Mean	SD	
Distension + steroid	Baseline	12	NR	NR	
Steroid injection		8	NR	NR	
Intervention	Time point	No. analysed	Mean	SD	p-value ^b
Distension + steroid	Unclear	11	There was no	significant difference between	NR
Steroid injection		7	groups (reported in the text)		
Outcome: Range of mo	ovement – passive ex	ternal rotation ^a			
Intervention	Time point	No. randomised	Mean	SD	
Distension + steroid	Baseline	12	NR	NR	
Steroid injection		8	NR	NR	
Intervention	Time point	No. analysed	Mean	SD	p-value ^b
Distension + steroid	Unclear	11	There was a si	gnificant improvement with	0.0007
Steroid injection		7	distension com in the text)	pared with steroid (reported	

a Graphical data only presented (for number achieving four levels of improvement).

Note: Other range of movements reported, which were not of relevance to this review and are therefore not presented in the data extraction tables, included passive flexion and extension.

Study: Gar	n 1998 ⁸⁶

Outcome: Quality of life

Not reported

Study: Gam 199886

Outcome: Other

Not reported

Study: Gam 199886

Outcome: Adverse events

Two cases of unacceptable pain (dropouts)

b *p*-value for between-group difference.

Study: Tveita 2008³⁶

Outcome: Pain

Not reported

Study: Tveita 2008 ³⁶						
Outcome: Function and disability measured using SPADI total score ^a						
Intervention	Time point	No. randomised	Mean	SD		
Arthrographic distension + steroid Steroid injection	Baseline	37 39	63 59	20 20		
Intervention	Time point	No. analysed	Mean	SD		
Arthrographic distension + steroid Steroid injection	6 weeks after last injection	37 39	26 20	19 17		

a Data were adjusted for baseline differences.

Study: Tveita 2008 ³⁶				
Outcome: Range of movement –	active abduction (°)			
Intervention	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	37	57	21
Steroid injection		39	55	20
Intervention	Time point	No. analysed	Mean	SD
Arthrographic distension + steroid	6 weeks after last	37	83	37
Steroid injection	injection	39	86	34
Outcome: Range of movement –	active external rotation	(°)		
Intervention	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	37	23	15
Steroid injection		39	22	16
Intervention	Time point	No. analysed	Mean	SD
Arthrographic distension + steroid	6 weeks after last	37	37	17
Steroid injection	injection	39	39	20
Outcome: Range of movement –	active internal rotation (~)		
Intervention	Time point	No. randomised	Mean	SD
Arthrographic distension + steroid	Baseline	37	46	15
Steroid injection		39	45	16
Intervention	Time point	No. analysed	Mean	SD
Arthrographic distension + steroid	6 weeks after last	37	66	18
Steroid injection	injection	39	68	17

Outcome: Range of movement – p	passive abduction (°)				
Intervention	Time point	No. randomised	Mean	SD	
Arthrographic distension + steroid	Baseline	37	31	11	
Steroid injection		39	31	11	
Intervention	Time point	No. analysed	Mean	SD	
Arthrographic distension + steroid	6 weeks after last	37	46	13	
Steroid injection	injection	39	12	17	
Outcome: Range of movement – p	passive external rotation	n (°)			
Intervention	Time point	No. randomised	Mean	SD	
Arthrographic distension + steroid	Baseline	37	19	13	
Steroid injection		39	16	14	
Intervention	Time point	No. analysed	Mean	SD	
Arthrographic distension + steroid	6 weeks after last	37	29	16	
Steroid injection	injection	39	27	17	
Outcome: Range of movement – p	passive internal rotation	(°)			
Intervention	Time point	No. randomised	Mean	SD	
Arthrographic distension + steroid	Baseline	37	34	14	
Steroid injection		39	32	13	
Intervention	Time point	No. analysed	Mean	SD	
Arthrographic distension + steroid	6 weeks after last	37	48	15	
Steroid injection	injection	39	45	12	

Study: Tveita 2008³⁶

Outcome: Quality of life

Not reported

Study: Tveita 200836

Outcome: Other

Not reported

Study: Tveita 2008³⁶

Outcome: Adverse events

Injections reported as very painful: distension: n=5, steroid: n=6

Other possible side effects reported: distension: n=14, steroid: n=20

Complaints of flushing or disturbances in heat regulation: distension: n=9, steroid: n=13

Minor loss of sensation and motor control loss in affected arm: distension: n=2; steroid: n=2

Loss of sleep, nausea or dizziness: number and treatment group unspecified

Glenohumeral joint infection: treatment group unspecified: n=1

[©] Queen's Printer and Controller of HMSO 2012. This work was produced by Maund et al. under the terms of a commissioning contract issued by the Secretary of State for Health.